Capital Partners Ii, Llc Lo... Net Worth

The estimated Net Worth of Capital Partners Ii, Llc Lo... is at least $332 mil dollars as of 2 July 2018. Capital Lo owns over 131,579 units of Tricida Inc stock worth over $332,171 and over the last 9 years Capital sold TCDA stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Capital Lo TCDA stock SEC Form 4 insiders trading

Capital has made over 3 trades of the Tricida Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Capital bought 131,579 units of TCDA stock worth $2,500,001 on 2 July 2018.

The largest trade Capital's ever made was buying 131,579 units of Tricida Inc stock on 2 July 2018 worth over $2,500,001. On average, Capital trades about 96,196 units every 275 days since 2016. As of 2 July 2018 Capital still owns at least 3,019,734 units of Tricida Inc stock.

You can see the complete history of Capital Lo stock trades at the bottom of the page.

Insiders trading at Tricida Inc

Over the last 6 years, insiders at Tricida Inc have traded over $198,373,537 worth of Tricida Inc stock and bought 7,174,449 units worth $105,536,837 . The most active insiders traders include David P Bonita, Advisors Llc Orbi Med Capit..., eHealthcare Capital Partners.... On average, Tricida Inc executives and independent directors trade stock every 8 days with the average trade being worth of $22,553. The most recent stock trade was executed by Robert J Alpern on 23 November 2022, trading 131,879 units of TCDA stock currently worth $27,695.

What does Tricida Inc do?

Complete history of Capital Lo stock trades at Aimmune Therapeutics Inc e Tricida Inc

Tricida Inc executives and stock owners

Tricida Inc executives and other stock owners filed with the SEC include:

• Gerrit Klaerner,
  President, Chief Executive Officer, Director
• Dawn Parsell,
  Executive Vice President - Clinical Development
• Geoffrey Parker,
  Chief Financial Officer, Executive Vice President
• Edward Hejlek,
  Senior Vice President
• Dr. Gerrit Klaerner Ph.D.,
  Founder, Pres, CEO & Exec. Director
• Dr. Dawn Parsell Ph.D.,
  Exec. VP of Clinical Devel.
• Geoffrey M. Parker,
  COO, CFO & Exec. VP
• Robert L. McKague J.D.,
  Exec. VP, Company Sec., Gen. Counsel & Chief Compliance Officer
• Dr. Wilhelm Stahl,
  Exec. VP & CTO
• Klaus Veitinger,
  Independent Chairman of the Board
• David Bonita,
  Independent Director
• Kathryn Falberg,
  Independent Director
• David Hirsch,
  Independent Director
• Sandra Coufal,
  Independent Director
• Robert Alpern,
  Independent Director
• Marc Cobo,
  Senior Vice President - Finance, Chief Accounting Officer
• Robert McKague,
  Executive Vice President, General Counsel, Secretary
• Edward J. Hejlek Esq., J.D.,
  Exec. VP of Intellectual Property
• Jackie Cossmon,
  VP of Investor Relations & Communications
• Annie Yoshiyama,
  VP of Fin. & Chief Accounting Officer
• Claire Lockey,
  Chief Dev. Officer and Sr. VP
• Brian M.Sibling Capital Fun...,
  
• Brian M.Sibling Capital Fun...,
  
• Brian M.Sibling Capital Ven...,
  
• Beek Jeroen B Van,
  Chief Comm Officer and Sr VP
• Steffen Pietzke,
  VP Fin & Chief Acct Officer
• Capital Partners Ii, Llc Lo...,
  
• Advisors Llc Orbi Med Capit...,
  
• Harbor Master Investors (Ca...,
  10% owner
• Wilhelm Stahl,
  EVP, Chief Tech Officer
• Brian M.Sibling Capital Ven...,
  
• Susannah Cantrell,
  EVP, Chief Comm. Officer
• Brian M.Sibling Capital Fun...,
  
• Brian M.Sibling Capital Fun...,
  
• Annie Yoshiyama,
  Senior VP, Finance and CAO
• Healthcare Capital Partners...,